Repros Therapeutics Inc  

(Public, NASDAQ:RPRX)   Watch this stock  
Find more results for RPRX
0.467
+0.002 (0.45%)
After Hours: 0.460 -0.007 (-1.52%)
Oct 18, 5:54PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.46 - 0.52
52 week 0.26 - 2.15
Open 0.48
Vol / Avg. 1.20M/1.68M
Mkt cap 17.57M
P/E     -
Div/yield     -
EPS -0.63
Shares 37.62M
Beta 0.40
Inst. own 20%
Nov 6, 2017
Q3 2017 Repros Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 14, 2017
Q2 2017 Repros Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -156.91% -114.23%
Return on average equity -1344.54% -140.06%
Employees 9 -
CDP Score - -

Address

2408 Timberloch Pl Ste B7
THE WOODLANDS, TX 77380-1021
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Officers and directors

Patrick P. Fourteau Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Larry M. Dillaha M.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Katherine A. Anderson CPA Chief Financial Officer, Chief Accounting Officer, Secretary
Age: 57
Bio & Compensation  - Reuters
Joachim F. Wernicke Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Daniel F. Cain Independent Director
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nola E. Masterson Independent Director
Age: 68
Bio & Compensation  - Reuters
Saira Ramasastry Independent Director
Age: 41
Bio & Compensation  - Reuters
Michael G. Wyllie Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters